ANAPTYSBIO INC's ticker is ANAB and the CUSIP is 032724106. A total of 139 filers reported holding ANAPTYSBIO INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,246,514 | -11.7% | 69,405 | +0.0% | 0.00% | – |
| Q2 2023 | $1,411,209 | -14.7% | 69,381 | -8.7% | 0.00% | – |
| Q1 2023 | $1,653,846 | -30.7% | 76,004 | -1.4% | 0.00% | -100.0% |
| Q4 2022 | $2,387,686 | +11.3% | 77,047 | -8.4% | 0.00% | 0.0% |
| Q3 2022 | $2,146,000 | +36.9% | 84,104 | +8.9% | 0.00% | – |
| Q2 2022 | $1,567,000 | -25.2% | 77,242 | -8.8% | 0.00% | – |
| Q1 2022 | $2,096,000 | -29.5% | 84,715 | -1.0% | 0.00% | -100.0% |
| Q4 2021 | $2,974,000 | +33.7% | 85,580 | +4.3% | 0.00% | – |
| Q3 2021 | $2,225,000 | +8.8% | 82,036 | +4.0% | 0.00% | – |
| Q2 2021 | $2,045,000 | -5.5% | 78,851 | -21.5% | 0.00% | – |
| Q1 2021 | $2,164,000 | +0.6% | 100,429 | +0.3% | 0.00% | – |
| Q4 2020 | $2,151,000 | +38.0% | 100,086 | -5.3% | 0.00% | – |
| Q3 2020 | $1,559,000 | -35.6% | 105,730 | -2.4% | 0.00% | -100.0% |
| Q2 2020 | $2,420,000 | +63.7% | 108,326 | +3.5% | 0.00% | – |
| Q1 2020 | $1,478,000 | -9.4% | 104,665 | +4.3% | 0.00% | – |
| Q4 2019 | $1,631,000 | -53.2% | 100,395 | +0.8% | 0.00% | -100.0% |
| Q3 2019 | $3,485,000 | -38.2% | 99,583 | -0.4% | 0.00% | -50.0% |
| Q2 2019 | $5,643,000 | -11.9% | 100,005 | +14.0% | 0.00% | 0.0% |
| Q1 2019 | $6,406,000 | +17.4% | 87,700 | +2.5% | 0.00% | 0.0% |
| Q4 2018 | $5,455,000 | -38.5% | 85,530 | -3.7% | 0.00% | 0.0% |
| Q3 2018 | $8,864,000 | +48.7% | 88,847 | +5.8% | 0.00% | 0.0% |
| Q2 2018 | $5,963,000 | -26.2% | 83,947 | +8.2% | 0.00% | 0.0% |
| Q1 2018 | $8,076,000 | -13.2% | 77,592 | -16.1% | 0.00% | 0.0% |
| Q4 2017 | $9,309,000 | +596.3% | 92,430 | +141.7% | 0.00% | – |
| Q3 2017 | $1,337,000 | +182.7% | 38,241 | +93.7% | 0.00% | – |
| Q2 2017 | $473,000 | +26.8% | 19,744 | +46.8% | 0.00% | – |
| Q1 2017 | $373,000 | – | 13,447 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 3,688,448 | $102,354,000 | 54.68% |
| Novo Holdings A/S | 3,033,504 | $84,180,000 | 8.96% |
| BVF INC/IL | 1,738,600 | $48,246,000 | 8.21% |
| Cormorant Asset Management, LP | 895,626 | $24,854,000 | 3.61% |
| Perceptive Advisors | 881,957 | $24,474,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 100,500 | $2,789,000 | 1.07% |
| ACUTA CAPITAL PARTNERS, LLC | 165,690 | $4,138,000 | 0.98% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 845,746 | $23,469,000 | 0.90% |
| Iguana Healthcare Management, LLC | 50,000 | $1,388,000 | 0.69% |
| Boxer Capital, LLC | 50,000 | $1,388,000 | 0.30% |